GLP-1 Drugmakers: Viking Therapeutics, Eli Lilly Face Clinical Trials
GLP-1 drug development is a high-stakes arena where companies like Eli Lilly and Viking Therapeutics are navigating critical clinical trial phases. Viking Therapeutics' VK2735 faces scrutiny in upcoming phase 3 trials, with potential for significant stock movement based on reported efficacy. Investors are closely watching these advancements in a rapidly growing pharmaceutical market.
* Watch Eli Lilly ( LLY ) as it navigates the competitive -1 market, with its stock currently showing a modest decline but maintaining key support levels. * Monitor Viking Therapeutics for upcoming phase 3 trial data for its VK2735 candidate, which could be a significant catalyst for its stock.